Tendersinfo Gulf

Filter Search

Healthcare and Medical

Location Summary Deadline
Germany Open House Drug Discount Agreements Goserelin, Atc L02ae03 2027-01-05
Germany Conclusion Of A Non-exclusive Discount Agreement Pursuant To Section 130a Para. 8 Sgb V For The Active Ingredient Nebivolol, (obg) Atc C07ab12 For The Period 01.03.2025 28.02.2027 2027-01-05
Germany Conclusion Of A Non-exclusive Discount Agreement Pursuant To Section 130a Para. 8 Sgb V For The Active Ingredient Atovaquone, (obg) Atc P01ax06 For The Period 01.03.2025 28.02.2027 2027-01-05
Germany Open House Drug Discount Agreements Botulinum Toxin Type A, Finished Drug Name Xeomin(r), Atc M03ax21 2027-01-05
Germany Conclusion Of A Non-exclusive Discount Agreement Pursuant To Section 130a Para. 8 Sgb V For The Active Ingredient Nitisinone, (obo) Atc A16ax04 For The Period 01.03.2025 28.02.2027 2027-01-05
Germany Conclusion Of A Non-exclusive Discount Agreement Pursuant To Section 130a Para. 8 Sgb V For The Active Substance Ustekinumab, (obg) Atc L04ac05 For The Period 01.03.2025 28.02.2027 2027-01-05
Germany Conclusion Of A Non-exclusive Discount Agreement Pursuant To Section 130a Para. 8 Sgb V For The Active Ingredient Erythropoietin Exclusively Epoetin Alfa, (obo) Atc B03xa01 For The Period 01.03.2025 28.02.2027 2027-01-05
Germany Conclusion Of A Non-exclusive Discount Agreement Pursuant To Section 130a Para. 8 Sgb V For The Active Ingredient Elbasvir + Grazoprevir, (obo) Atc J05ap54 For The Period 01.03.2025 28.02.2027 2027-01-05
Germany Drug Discount Agreements Pursuant To Section 130a Para. 8 Sgb V Within The Framework Of Open House Procedures 2027-01-05
Germany Conclusion Of A Non-exclusive Discount Agreement Pursuant To Section 130a Para. 8 Sgb V For The Active Ingredient Bempedoic Acid + Ezetimibe, (obo) Atc C10ba10 For The Period 01.03.2025 28.02.2027 2027-01-05
Whats app